January 19th, 2011
What PROSPECT Doesn’t Tell Us
Richard A. Lange, MD, MBA and L. David Hillis, MD
The PROSPECT trial provides some interesting insights about the mechanisms of thrombotic coronary artery disease, but how, if at all, should it change practice? Here are what the findings do and do not demonstrate: What the PROSPECT study says: In ACS patients treated with PCI, major adverse cardiovascular events that occurred during a median follow-up of 3.4 years were as […]
NEJM Journal Watch — Recent Cardiology Articles- Atrial Fibrillation and Stable Coronary Artery Disease — What Is the Optimal Anticoagulation–Antiplatelet Regimen?
- β-Blockers After Myocardial Infarction
- Updated Guideline for Perioperative Cardiovascular Management of Patients Undergoing Noncardiac Surgery
- Strategies and Criteria for the Diagnosis and Management of Myocarditis
- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?